 |
0 Diseases |  |
123 Trials |
|
123 Trials |  |
2738 News |  |
| «12...345678910111213...4142» |
- | anastrozole / Generic mfg., triptorelin / Generic mfg.
Journal: Sex steroids regulate liver fat content and body fat distribution in both men and women: a study in transgender persons. (Pubmed Central) - Jul 18, 2023
Sex hormones regulate liver fat content and visceral fat in men and women.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Retrospective data, Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: CDK4/6 Inhibitors in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: An Updated Network Meta-Analysis and Cost-Effectiveness Analysis. (Pubmed Central) - Jul 14, 2023
The Palbo + NSAI and Ribo + NSAI groups were not cost-effective unless drug prices were adjusted to 50% or 10% of current prices ($320.67 per cycle or $264.60 per cycle). (5) Others: We have prospectively registered the study with the PROSPERO, and the PROSPERO registration number is CRD42023399342.
- ||| Apristor (onapristone XR) / Context Therap
Enrollment change: OATH: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer (clinicaltrials.gov) - Jul 12, 2023
P2, N=14, Active, not recruiting, Sponsor: Thomas Jefferson University
(5) Others: We have prospectively registered the study with the PROSPERO, and the PROSPERO registration number is CRD42023399342. N=25 --> 14
- anastrozole / Generic mfg.
Anastrozole modulates mitochondrial activity via Inhibitory action on mitochondrial permeability transition pore opening : An Initial Perspective on repurposive drug therapeutic. (Exhibitions Hall (ICC)) - Jul 11, 2023 - Abstract #SSIEM2023SSIEM_600;
No definitive therapy that directly modulates the function of mitochondria either by increasing the proportion of healthy mitochondria or by modulating the effects of mutated variants. Anastrozole seems to be a promising agent in ameliorating the in- vitro phenotype by regulating the activity across the mtPTP.
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Journal: The genomic landscape associated with resistance to aromatase inhibitors in breast cancer. (Pubmed Central) - Jul 7, 2023
Pathway analysis revealed HSD3B1 to be involved in estrogen biosynthesis. This study reveals the involvement of key genes that might be associated with the development of AI resistance in ER-positive breast cancers and hence may act as a potential prognostic and diagnostic biomarker for these patients.
- | Kisqali (ribociclib) / Novartis
Trial completion, Enrollment change, Metastases: AMICA: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (clinicaltrials.gov) - Jul 7, 2023
P2, N=56, Completed, Sponsor: German Breast Group
This study reveals the involvement of key genes that might be associated with the development of AI resistance in ER-positive breast cancers and hence may act as a potential prognostic and diagnostic biomarker for these patients. Active, not recruiting --> Completed | N=150 --> 56
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study of Abemaciclib in Indian Women With Advanced Breast Cancer (clinicaltrials.gov) - Jul 5, 2023
P4, N=200, Completed, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed | N=150 --> 56 Recruiting --> Completed
- || Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: AMALEE: Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (clinicaltrials.gov) - Jul 3, 2023
P2, N=376, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial completion date: Dec 2025 --> Jul 2024
- Platelet-Rich Plasma (PRP) for the Treatment of Endocrine Therapy-Induced Alopecia (EIA) and Permanent Chemotherapy-Induced Alopecia (pCIA) in Breast Cancer Patients () - Jul 3, 2023 - Abstract #WCD2023WCD_5853;
We see diffusion of treatment effect when one side of the scalp is treated which is in line with studies of PRP for androgenetic alopecia. Further studies are needed to elucidate the use of PRP in combination with medical therapies
- |||| Kisqali (ribociclib) / Novartis
Trial completion, Metastases: RIGHT Choice: Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 26, 2023
P2, N=223, Completed, Sponsor: Novartis Pharmaceuticals
Further studies are needed to elucidate the use of PRP in combination with medical therapies Active, not recruiting --> Completed
- | Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trial completion date, Combination therapy, Metastases: DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 22, 2023
P1b, N=139, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed Trial completion date: Aug 2023 --> Nov 2025
- || letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Review, Journal, HEOR: Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review. (Pubmed Central) - Jun 19, 2023
Trial completion date: Aug 2023 --> Nov 2025 In recent years there has been an increase in studies focused on health-related quality of life, and the evidence pointed to relevant information on health-related quality of life and the use of endocrine therapy, tamoxifen in combination with aromatase inhibitors, as well as aromatase inhibitor alone and the use of cyclin-dependent kinase 4 and 6.
- | Biomarker, Enrollment open: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov) - Jun 18, 2023
P2, N=500, Recruiting, Sponsor: University of Miami
In recent years there has been an increase in studies focused on health-related quality of life, and the evidence pointed to relevant information on health-related quality of life and the use of endocrine therapy, tamoxifen in combination with aromatase inhibitors, as well as aromatase inhibitor alone and the use of cyclin-dependent kinase 4 and 6. Not yet recruiting --> Recruiting
- ||| anastrozole / Generic mfg.
P3 data, Journal: Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. (Pubmed Central) - Jun 16, 2023
Continuing adjuvant anastrozole for an additional 5 years after 5 years of initial treatment with anastrozole or tamoxifen followed by anastrozole was well tolerated and improved DFS. Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer.
- || vepdegestrant (ARV-471) / Arvinas, Pfizer
Trial primary completion date, Surgery: TACTIVE-N: A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery (clinicaltrials.gov) - Jun 15, 2023
P2, N=150, Recruiting, Sponsor: Arvinas Inc.
Although no difference in overall survival was observed as in other trials, extended anastrozole therapy could be one treatment choice in postmenopausal patients with hormone receptor-positive breast cancer. Trial primary completion date: Dec 2023 --> Jul 2024
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jun 15, 2023
P3, N=493, Active, not recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Dec 2023 --> Jul 2024 Trial completion date: Sep 2023 --> Sep 2024
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date: Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jun 15, 2023
P2, N=161, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Sep 2023 --> Sep 2024 Recruiting --> Active, not recruiting | N=29 --> 161 | Trial primary completion date: Jun 2023 --> Jan 2024
- ||||| giredestrant (GDC-9545) / Roche
New P2 trial: PREcoopERA: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (clinicaltrials.gov) - Jun 9, 2023
P2, N=220, Not yet recruiting, Sponsor: ETOP IBCSG Partners Foundation
- | NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date: CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) - Jun 7, 2023
P=N/A, N=379, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting | N=29 --> 161 | Trial primary completion date: Jun 2023 --> Jan 2024 Completed --> Active, not recruiting | Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Jan 2023 --> Jan 2024
- | Epidaza (chidamide) / Chipscreen
New trial, Combination therapy: A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy (clinicaltrials.gov) - Jun 6, 2023
P=N/A, N=60, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
New P3 trial: Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01) (clinicaltrials.gov) - Jun 6, 2023
P3, N=766, Not yet recruiting, Sponsor: Fudan University
- ||| Kisqali (ribociclib) / Novartis
P3 data, Journal: Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib?+?endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. (Pubmed Central) - Jun 5, 2023
P3
NATALEE includes the broadest population of patients with HR+/HER2- EBC of any Phase III trial currently evaluating adjuvant CDK4/6 inhibitor treatment. ClinicalTrials.gov identifier: NCT03701334 (https://clinicaltrials.gov/ct2/show/NCT03701334).
- ||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
P3 data, Journal, Metastases: Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Jun 5, 2023
P3
ClinicalTrials.gov identifier: NCT03701334 (https://clinicaltrials.gov/ct2/show/NCT03701334). Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape.
- ||||||| Kisqali (ribociclib) / Novartis
Trial completion, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jun 5, 2023
P3, N=672, Completed, Sponsor: Novartis Pharmaceuticals
Our findings suggest that dalpiciclib plus letrozole or anastrozole could be a novel standard first-line treatment for patients with hormone receptor-positive, HER2-negative advanced breast cancer, and is an alternative option to the current treatment landscape. Active, not recruiting --> Completed
- | anastrozole / Generic mfg.
Trial primary completion date: A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) (clinicaltrials.gov) - May 31, 2023
P=N/A, N=1046, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Trial primary completion date: Jun 2022 --> Dec 2023
- || anastrozole / Generic mfg., fulvestrant / Generic mfg.
Trial completion, Surgery: Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. (clinicaltrials.gov) - May 19, 2023
P2, N=42, Completed, Sponsor: University of Kansas Medical Center
Trial primary completion date: Jun 2022 --> Dec 2023 Active, not recruiting --> Completed
- | anastrozole / Generic mfg.
Journal: Dihydrotestosterone, and Not Testosterone, Enhances the LPS-Induced Inflammatory Cytokine Gene Expression in Human Adipocytes. (Pubmed Central) - May 16, 2023
DHT and A/T dramatically enhance LPS-induced inflammatory cytokine expression in human-derived adipocytes. These results confirm the involvement of sex hormones in adipose tissue inflammation, suggesting a specific role for non-aromatizable androgens as the amplificatory sex hormones of the inflammatory response.
- || Imlygic (talimogene laherparepvec) / Amgen
Enrollment closed, Trial completion date, Trial primary completion date: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - May 15, 2023
P1b, N=20, Active, not recruiting, Sponsor: University of California, San Francisco
These results confirm the involvement of sex hormones in adipose tissue inflammation, suggesting a specific role for non-aromatizable androgens as the amplificatory sex hormones of the inflammatory response. Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
- || anastrozole / Generic mfg.
TROG study 👇 with Arimidex Primary endpoint 👉 Local control Results pending.... https://t.co/dtg72kdfLV (Twitter) - May 14, 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Journal: Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors. (Pubmed Central) - May 13, 2023
Recruiting --> Active, not recruiting | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Contrary to Ana and Let, this study highlights the potential benefits of combining CBD with Exe to improve breast cancer treatment and opens up the possibility of new therapeutic approaches comprising the use of cannabinoids.
- anastrozole / Generic mfg.
VTE and Testosterone Therapy: What is the Risk? (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_2083;
At the time of presentation, he was on IM testosterone cypionate 200mg weekly and anastrozole with total testosterone970 ng/dL, free testosterone 298 pg/mL, undetectable estradiol, and hematocrit 41.5%...2021; 199:123-131. doi:10.1016/j.thromres.2020.12.029
- anastrozole / Generic mfg., tamoxifen / Generic mfg.
Complex Treatment of Recurrent Gynecomastia in an Affirmed Male with 46XX Ovotesticular Difference of Sexual Differentiation (DSD). (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1742;
Recurrent hemorrhagic cysts in the ovotestis were likely due to physiologic stimulation and tamoxifen1 as well as elevated estradiol. Treatment with a GnRHa and testosterone offered a reversible, non-surgical method to suppress endogenous sex hormones contributing to gynecomastia while continuing male pubertal development.1.PMID: 16254040
- anastrozole / Generic mfg.
Loss of Inhibin Negative Feedback in the Pituitary Leads to Enhanced Ovulation but Pregnancy Failure in Mice (W-178B) - May 11, 2023 - Abstract #ENDO2023ENDO_1136;
We are currently more thoroughly characterizing the maternal hormonal environment throughout gestation and investigating placental structure/function to gain more insight into the precise nature of the pregnancy failure. Our results will show how loss of inhibin action in the pituitary impede embryo survival and whether pregnancy loss is linked to increases in FSH.
- |||| camizestrant (AZD9833) / AstraZeneca
Trial primary completion date, Circulating tumor DNA: Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov) - May 11, 2023
P3, N=300, Recruiting, Sponsor: AstraZeneca
Our results will show how loss of inhibin action in the pituitary impede embryo survival and whether pregnancy loss is linked to increases in FSH. Trial primary completion date: Jul 2024 --> Jan 2025
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: CardioVOLT: Cardiovascular Outcomes of Low Testosterone (clinicaltrials.gov) - May 11, 2023
P=N/A, N=379, Completed, Sponsor: University of Colorado, Denver
Trial primary completion date: Jul 2024 --> Jan 2025 Recruiting --> Completed | Trial completion date: Nov 2022 --> Jan 2023 | Trial primary completion date: Sep 2022 --> Jan 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Journal: Parahydrogen in Reversible Exchange Induces Long-Lived N Hyperpolarization of Anticancer Drugs Anastrozole and Letrozole. (Pubmed Central) - May 10, 2023
The hyperpolarization can exceed 10%, corresponding to N signal enhancement of over 280,000-fold at a clinically relevant magnetic field of 1 T. This sensitivity gain enables polarization studies at naturally abundant N enrichment level (0.4%). Moreover, the nitrile N sites enable long-lasting polarization storage with [N]T over 9 min, enabling signal detection from a single hyperpolarization cycle for over 30 min.
- | anastrozole / Generic mfg., capecitabine / Generic mfg.
Preclinical, Journal: Amalgamation of quercetin with anastrozole and capecitabine: A novel combination to treat breast and colon cancers - An in vitro study. (Pubmed Central) - May 10, 2023
The natural compound used in the present study is effective in treating breast and colon cancer at minimal concentrations in combination with the drugs. This combinational treatment appears to be reported for the first time in the present study.
- || Soltamox (tamoxifen citrate) / Jazz, Firmagon (degarelix) / Astellas, Ferring, Verzenio (abemaciclib) / Eli Lilly
Trial initiation date: ETHAN - ET for Male BC (clinicaltrials.gov) - May 9, 2023
P2, N=60, Not yet recruiting, Sponsor: Jose Pablo Leone
This combinational treatment appears to be reported for the first time in the present study. Initiation date: Feb 2023 --> Oct 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Phase classification: Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer (clinicaltrials.gov) - May 8, 2023
P=N/A, N=51, Completed, Sponsor: University of Maryland, Baltimore
Initiation date: Feb 2023 --> Oct 2023 Phase classification: P2 --> P=N/A
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - May 6, 2023
P2, N=38, Active, not recruiting, Sponsor: Emory University
Phase classification: P2 --> P=N/A Trial completion date: Aug 2023 --> Dec 2023 | Trial primary completion date: Aug 2023 --> Dec 2023
- | anastrozole / Generic mfg., isotretinoin oral / Generic mfg.
Journal, Metastases: X-linked hypophosphatemic rickets with advanced bone age treated with aromatase inhibitor. (Pubmed Central) - May 4, 2023
Isotretinoin may accelerate skeletal maturation during puberty in an adolescent with X-linked hypophosphatemic rickets. Aromatase inhibitors showed to be a reasonable strategy to stabilize bone age and minimize height impairment in an adolescent with X-linked hypophosphatemic rickets.
- | Apristor (onapristone XR) / Context Therap
Enrollment closed: OATH: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer (clinicaltrials.gov) - May 3, 2023
P2, N=25, Active, not recruiting, Sponsor: Thomas Jefferson University
Aromatase inhibitors showed to be a reasonable strategy to stabilize bone age and minimize height impairment in an adolescent with X-linked hypophosphatemic rickets. Recruiting --> Active, not recruiting
- || saracatinib (AZD0530) / AstraZeneca
P2 data, Journal, Metastases: Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. (Pubmed Central) - May 1, 2023
There was no observed beneficial effect on bone metastases. CRUKE/11/023, ISRCTN23804370.
- | Biomarker, New P2 trial: NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - May 1, 2023
P2, N=81, Not yet recruiting, Sponsor: Washington University School of Medicine
- | anastrozole / Generic mfg.
Journal: Kinin B and B Receptors Activation Sensitize the TRPA1 Channel Contributing to Anastrozole-Induced Pain Symptoms. (Pubmed Central) - Apr 28, 2023
TRPA1 seems to be sensitized by mechanisms dependent on the activation of PLC/PKC, and PKA due to kinin receptors stimulation in anastrozole-treated animals. Thus, regulating this signaling pathway could contribute to alleviating AIs-related pain symptoms, patients' adherence to therapy, and disease control.
- Kisqali (ribociclib) / Novartis
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4289;
Ribociclib liver toxicity occurs mainly during the first 6 months of treatment and takes several months to recover. >
- Symptom burden of patients with breast cancer on adjuvant hormone therapy: A preliminary report. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4151;
P=N/A
Based on the BCPT instrument subscales, musculoskeletal symptoms tend to be the most intrusive, with the highest mean score. Symptom burden was inversely related to higher self-efficacy represented by LORIG scores.
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Longitudinal trends in serum calcium, parathormone and bone mineral density in breast cancer survivors on aromatase inhibitor therapy: A single institutional cohort study. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4146;
No significant increase in PTH levels occurred during AI therapy and majority of patients with clinically significant PTH elevation also had CKD, which may have contributed also to elevation of PTH level and low urinary calcium excretion. >
- letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Therapy decision-making after pre-operative endocrine therapy in HR+ HER2- early breast cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4136;
Mature data of long-term pts outcome are awaited. >
- anastrozole / Generic mfg., tamoxifen / Generic mfg., fulvestrant / Generic mfg.
Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226. (On Demand | Hall A; Poster Bd # 297) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3268;
P3
In contrast, CA 15-3 is only modestly prognostic at BL, but is prognostic after 3 cycles of treatment. These hypothesis-generating data suggest further study is needed to determine how these biomarkers should be employed in a complementary manner to monitor response to systemic therapy in HR+ MBC.